Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Core Insights - Nanobiotix, a late-stage clinical biotechnology company, is focused on pioneering nanoparticle-based approaches to enhance treatment options for cancer and other significant diseases [1][2]. Company Overview - Nanobiotix was incorporated in 2003 and is headquartered in Paris, France. The company has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020. It also has subsidiaries in Cambridge, Massachusetts, among other locations [3]. - The company owns over 25 patent families related to three nanotechnology platforms, which have applications in oncology, bioavailability and biodistribution, and disorders of the central nervous system [3]. Upcoming Events - Company management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 9:00 am EDT / 3:00 pm CEST in New York, NY. Presenters will include Laurent Levy, CEO, and Bart van Rhijn, Chief Financial & Business Officer [1]. - The event will be webcast live, and a replay will be available afterward [1].